Julia Guzmán-Puche

Julia Guzmán-Puche

Auto-generated profile, based on publicly available information

Julia Guzmán-Puche

Microbiology Unit, Reina Sofía University Hospital, Cordoba, Spain

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2017 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
BGBelén Gutiérrez-Gutiérrez
Belén Gutiérrez-Gutiérrez
ESElena Salamanca
Elena Salamanca
MCMarina de Cueto
Marina de Cueto
PHPo-Ren Hsueh
Po-Ren Hsueh
PVPierluigi Viale
Pierluigi Viale
EJE Jové
E Jové

8 November 2017 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
ACAngela Cano
Angela Cano
BGBelén Gutiérrez-Gutiérrez
Belén Gutiérrez-Gutiérrez
IMIsabel Machuca
Isabel Machuca
IGIrene Gracia-Ahufinger
Irene Gracia-Ahufinger
EPElena Perez-Nadales
Elena Perez-Nadales
JTJulian Torre-Cisneros
Julian Torre-Cisneros
The management and indication of empirical treatment in Klebsiella pneumoniae-carbapenemase producing K. pneumoniae (KPC-Kp) colonized patients should be improved. A prospective cohort of 94 patients colonized by KPC-Kp was followed for 90 days to validate: (i) the Giannella risk score (GRS) to predict the development of any type of KPC-Kp infection and (ii) the INCREMENT-CPE score (ICS) to predict 30-day mortality in patients with infection. Both scores were combined in order to recommend appropriate empirical treatment. The predictive ability of the scores was measured by calculating the area under the receiver operating characteristic (AUROC) curve. The GRS showed an AUROC curve for infection due to KPC-Kp of 0.92 (CI 95%: 0.87–0.98). The optimal cutoff point was fixed at < 7 and ≥ 7 (92.9% sensitivity, 84.8% specificity); infection developed in 6.3% patients in the 0–6 GRS group and in 84.8% patient in the ≥ 7 GRS group. According to the ICS, the severity of the infection was also significantly higher in the ≥ 7 GRS group. The ICS showed an AUROC of 0.78 (95% CI: 0.65–0.91) for 30-day all-cause mortality among patients with infection. A CART analysis confirmed the GRS cutoff point at 7, and selected ≥ 12 points to predict a KPC-Kp infection with a high ICS. Our results validate the GRS and ICS for indicating empirical therapy in KPC-Kp- colonized patients

1 August 2017 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
IMIsabel Machuca
Isabel Machuca
BGBelén Gutiérrez-Gutiérrez
Belén Gutiérrez-Gutiérrez
IGIrene Gracia-Ahufinger
Irene Gracia-Ahufinger
FEFrancisco Rivera Espinar
Francisco Rivera Espinar
ÁCÁngela Cano
Ángela Cano
JTJulián Torre-Cisneros
Julián Torre-Cisneros
Combination therapy including colistin and a carbapenem has been found to be associated with lower mortality in the treatment of bloodstream infections (BSI) due to KPC-producing Klebsiella pneumoniae when the isolates show a meropenem or imipenem MIC of <16 mg/liter. However, the optimal treatment of BSI caused by colistin- and high-level carbapenem-resistant KPC-producing K. pneumoniae is unknown. A prospective cohort study including episodes of bacteremia caused by colistin-resistant and high-level meropenem-resistant (MIC ≥ 64 mg/liter) KPC-producing K. pneumoniae diagnosed from July 2012 to February 2016 was performed. The impact of combination therapy on crude 30-day mortality was analyzed by Cox regression using a propensity score as a covariate to control for indication bias and in an inverse probability of treatment weighting (IPTW) cohort. The study sample comprised 104 patients, of which 32 (30.8%) received targeted monotherapy and 72 (69.2%) received targeted combination therapy; none of them received either colistin or a carbapenem. The 30-day crude mortality rate was 30.8% (43.8% in patients treated with monotherapy and 25% in patients receiving combination therapy). In the Cox regression analysis, 30-day mortality was independently associated with septic shock at BSI onset (hazard ratio [HR], 6.03; 95% confidence interval [CI], 1.65 to 21.9; P = 0.006) and admission to the critical care unit (HR, 2.87; 95% CI, 0.99 to 8.27; P = 0.05). Targeted combination therapy was associated with lower mortality only in patients with septic shock (HR, 0.14; 95% CI, 0.03 to 0.67; P = 0.01). These results were confirmed in the Cox regression analysis of the IPTW cohort. Combination therapy is associated with reduced mortality in patients with bacteremia due to colistin-resistant KPC-producing K. pneumoniae with high-level carbapenem resistance in patients with septic shock.

NMNicolás Francisco Fernández Martínez
Nicolás Francisco Fernández Martínez
SCSheila Cárcel-Fernández
Sheila Cárcel-Fernández
CMCarmen De la Fuente Martos
Carmen De la Fuente Martos
RMRafael Ruiz Montero
Rafael Ruiz Montero
BGBernardo R. Guzmán-Herrador
Bernardo R. Guzmán-Herrador
ISInmaculada Salcedo-Leal
Inmaculada Salcedo-Leal
Multidrug-resistant Gram-negative bacteria (MDR-GNB) are microorganisms that have acquired resistance to extended-spectrum antibacterials and constitute an emerging threat to public health. Although carriers are an important source of transmission in healthcare settings, data about risk factors for MDR-GNB carriage are limited. Therefore, we aimed to identify risk factors for MDR-GNB carriage upon intensive care unit (ICU) admission and to optimise screening strategies. We conducted a case–control study. Admissions of adult patients to the ICU of a 1000-bed hospital during a year were included. We collected sociodemographic, clinical and microbiological data and performed a multivariate logistic regression model. A total of 1342 patients resulted in 1476 episodes of ICU admission, 91 (6.2%) of whom harboured MDR-GNB (38.5% women; median age 63.9 years). The most frequently isolated pathogens were Escherichia coli (57%) and Klebsiella pneumoniae (16%). The most frequent resistance mechanism was production of extended-spectrum beta lactamases. MDR-GNB carriage was associated to liver cirrhosis (OR 6.54, 95% CI 2.17–19.17), previous MDR-GNB carriage (OR 5.34, 1.55–16.60), digestive surgery (OR 2.83, 1.29–5.89) and length of hospital stay (OR 1.01 per day, 1.00–1.03). Several risk factors for MDR-GNB carriage upon admission to a high-risk setting were identified; the main comorbidity was liver cirrhosis.

14 January 2022 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
JGJ. Guzmán-Puche
J. Guzmán-Puche
EPE. Pérez-Nadales
E. Pérez-Nadales
MPM. Pérez-Vázquez
M. Pérez-Vázquez
MCM. Causse
M. Causse
IGI. Gracia-Ahufinger
I. Gracia-Ahufinger
LMLuis Martínez Martínez
Luis Martínez Martínez

1 March 2021 in Journal of Global Antimicrobial Resistance
Verified
Journal Article
Open access
JGJulia Guzmán-Puche
Julia Guzmán-Puche
RJRim Jenayeh
Rim Jenayeh
MPMaría Pérez-Vázquez
María Pérez-Vázquez
MCManuel- Causse
Manuel- Causse
FAFerjani Asma
Ferjani Asma
LMLuis Martínez-Martínez
Luis Martínez-Martínez
Objective: There is very limited information about OXA-48-producing Klebsiella oxytoca. The aim of this study was to describe the phenotypic and molecular characterization of OXA-48-producing K. oxytoca isolates that caused an outbreak in a hospital in Tunisia. Methods: Nineteen OXA-48-producing K. oxytoca were isolated from 2013 to 2016 in the University Hospital Farhat Hached, Sousse, Tunisia. Antibiotic susceptibility testing was performed by broth microdilution. Carbapenemase activity was investigated using the modified carbapenem inactivation method (mCIM). Phenotypic tests were also carried out to detect extended-spectrum beta-lactamases. PCR was used to test for the presence of carbapenemase genes (bla(IMP), bla(VIM), bla(NDM), bla(SPM), bla(AIM), bla(DIM), bla(GIM), bla(SIM), bla(KPC,) bla(BIC) and bla(OXA-48)). Genetic relatedness among isolates was investigated using repPCR. Whole genome sequencing (WGS) was performed in three representative isolates. Results: mCIM was positive in all isolates. None of the isolates presented an ESBL phenotype. All strains were susceptible to cefoxitin, ceftazidime, cefepime, aztreonam, imipenem, meropenem, fluoroquino-lones, aminoglycosides and colistin, and resistant to piperacillin-tazobactam, ertapenem, ticarcillin and ampicillin-sulbactam. All isolates presented the bla(OXA-48)gene located in a ca. 63 kb IncL plasmid, which carried no additional resistance genes. They belonged to the new ST220. Conclusion: Isolates from this study did not co-express an ESBL, which could complicate their detection in clinical laboratories. As OXA-48 has been mostly reported in K. pneumoniae there is a risk that the production of this enzyme is not suspected in the less common species K. oxytoca. These difficulties could play an important role in the hidden spread of this enzyme. (C) 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.